Építés alatt – nem éles oldal
Belépés
Toborzás még nem indult1/2. fázis

Standard Treatment Associated With Phage Therapy Versus Placebo for Diabetic Foot Ulcers Infected by S. Aureus

A legfontosabb adatok

Ki végzi
Centre Hospitalier Universitaire de Nīmes
Hol
Franciaország7 helyszín, 1 országbanVálassz országot a helyszínekhez
Állapot
Toborzás még nem indult
Fázis
1/2. fázis
Résztvevők
60 fő, tervezett
Kezdés
2026. szept. 1.
Várható befejezés
2028. nov.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Topical anti-Staphylococcus bacteriophage therapy
  • Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy
A regiszteradat frissítve
2026. március 20.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with type 1 or type 2 diabetes who have an infected foot wound with S. aureus. It compares a phage cocktail put on the wound with a placebo, both added to standard treatment.

Életkor
18 years and older.
Nem
All sexes.
A betegség stádiuma
A nerve-damage (neuropathic) foot wound below the ankle, present for >2 weeks, with a surface area ≥ 0,5 cm2. SINBAD class S (0 or 1), I (0 or 1), N (1), B (1), A (0 or 1), D (1). IWGDF/IDSA grade 2 or 3 infection with no bone infection. No poor blood flow, or only non-critical: ankle arterial pressure > 50 mm Hg, toe systolic pressure > 30 mm Hg, or TcpO2 > 30 mm Hg.
Korábbi kezelés
No other trial in the past three months.
Biomarker vagy leletérték
The wound must be infected by S. aureus (MSSA or MRSA), alone or with other bacteria, up to 3 bacteria in total. A phagogram test must show the strains respond to at least one phage (PP1493 and/or PP1815). Negative pregnancy test before treatment.

A részvétel fő kizáró okai

  • Bone infection (osteomyelitis) or joint inflammation (arthritis) linked to the wound
  • Wound not infected by S. aureus, or infected by more than 3 bacteria
  • Pregnant, giving birth or breastfeeding, or planning pregnancy during treatment and 1 month after
  • Not willing to use effective birth control during and 1 month after the study drug
  • Under guardianship or judicial protection

A regiszter feltételei, szó szerint

Mind a 29 feltétel megnézéseKevesebb

Egyéb feltételek

  • Participant pre-inclusion criteria:
  • The patient must have given his/her informed and signed consent
  • The patient must be insured or beneficiary of a health insurance plan
  • The patient is at least 18 years old
  • The patient has type 1 or type 2 diabetes
  • The patient is hospitalized/consulting in a participating centre
  • The patient has a wound below the ankle that has be evolving for >2 weeks
  • The patient has a neuropathic foot wound, classified S (0 or 1), I (0 or 1), N (1), B (1), A (0 or1) and D (1) according to the SINBAD classification,; without ischaemia or with non-critical ischaemia defined by: ankle arterial pressure > 50 mm Hg or toe systolic arterial pressure > 30 mm Hg or TcpO2 > 30 mm Hg ); with a surface area ≥ 0,5 cm2; With IWGDF/IDSA grade 2 or 3 infection without osteomyelitis (normal radiography*)
  • Females of childbearing potential or Sexually active males with partner of childbearing potential: commitment to consistently and correctly use an acceptable method of birth control (oral, transdermal, systemic or implant contraception birth control, intrauterine devices) for 1 month after the last study drug administration
  • Negative pregnancy test must be obtained before starting any experimental drug
  • Females of non-childbearing potential: either surgically sterilized or at least 1 year postmenopausal (amenorrhea duration at least 12 months); Participant final inclusion criteria:
  • The patient has a neuropathic foot wound:; Classified S (0 or 1), I (0 or 1), N (1), B (1), A (0 or1) and D (1) according to the SINBAD classification,
  • without ischaemia or with non-critical ischaemia defined by: ankle arterial pressure > 50 mm Hg or toe systolic arterial pressure > 30 mm Hg or TcpO2 > 30 mm Hg )
  • with a surface area ≥ 0,5 cm2; With IWGDF/IDSA grade 2 or 3 infection without osteomyelitis
  • The patient's wound is monoinfected by methicillin-resistant or susceptible S. aureus (MSSA or MRSA ), or infected by MSSA or MRSA and other bacteria (a total of 3 bacteria when accounting for MSSA or MRSA)
  • The Phagogram of the patient demonstrated that the strains are susceptible to at least one phage(PP1493 and/or PP1815); Participant pre-exclusion criteria:
  • The patient is participating in, or has participated in over the past three months, another trial
  • The patient is participating in, or has participated in over the past three months, another study that may interfere with the results or conclusions of this study
  • The patient is in an exclusion period determined by a previous study
  • The patient is under judicial protection, or is an adult under guardianship
  • It is impossible to correctly inform the patient
  • The patient refuses to sign the consent
  • The patient is pregnant, parturient or breastfeeding. Patients should not be enrolled if they plan to become pregnant during the treatment period and 1 month after the last administration of study drug
  • Women/Men refusing to use an effective contraception during and1 month after the last administration of study drug; Participant final exclusion criteria:
  • The patient refuses to participate to the study
  • The patient is pregnant, parturient or breastfeeding. Patients should not be enrolled if they plan to become pregnant during the treatment period and 1 month after the last administration of study drug
  • Women/Men refusing to use an effective contraception during and1 month after the last administration of study drug
  • Patients with diabetic foot wounds associated with clinical or radiographic signs of arthritis or osteomyelitis*
  • Patient is not infected by S. aureus or infected by more than 3 bacteria even if the culture isolates a S. aureus

Ez a vizsgálat jelenleg itt érhető el: Franciaország.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The primary objective of this study is to compare the efficacy of standard treatment associated with a topical anti-staphylococcal bacteriophage cocktail versus standard treatment plus placebo for diabetic foot ulcers monoinfected by methicillin-resistant or susceptible S. aureus (MRSA or MSSA) as measured by the relative reduction in wound surface area (%) at 12 weeks.

A vizsgálat 2 csoportja

  • Phage therapyA vizsgált kezelés

    Patients randomized to this arm will have phage therapy. Intervention: Topical anti-Staphylococcus bacteriophage therapy

    Kezelés: Topical anti-Staphylococcus bacteriophage therapy

  • PlaceboPlacebo, összehasonlításként

    Patients randomized to this arm will have placebo therapy anologous to that of the experimental arm. Intervention: Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy

    Kezelés: Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
Comparison of the Efficacy of Standard Treatment Associated With Phage Therapy Versus Standard Treatment Plus Placebo for Diabetic Foot Ulcers Monoinfected by Staphylococcus Aureus: a Randomized, Multi-centre, Controlled, 2-parallel-group, Double-blind, Superiority Trial
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
A regiszteradat frissítve
2026. március 20.